Low-Dose Radiation Therapy to the Whole Liver With Gemcitabine and Cisplatin in IHC

Inclusion Criteria: * Histologic diagnosis of mass-forming IHC. OR * Histologic diagnosis of adenocarcinoma of the liver in setting of negative colonoscopy, upper endoscopy, mammography (females), or cross-sectional imaging for primary disease. * Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension as ≥10 mm (≥1 cm) with spiral CT scan, MRI. See Section 8 for the evaluation of measurable disease. * Locally advanced disease (portal lymph node disease, multifocal intrahepatic lesions, or major vascular invasion) AND no evidence of omental, peritoneal, or pelvic metastases. * Other sites of metastatic disease (e.g. lung, distant lymph nodes, bone) are allowed. * No prior chemotherapy, radiotherapy, or surgical therapy. * ECOG performance status ≤ 1 (Karnofsky ≥70%). See Appendix A. * Life expectancy of greater than six months. * Patients must have normal organ and marrow function as defined below: * leukocytes≥3,000/mcL * absolute neutrophil count≥1,500/mcL * platelets ≥100,000/mcL * hemoglobin≥9.0 g/dL * total bilirubin≤2.0 mg/dL * AST(SGOT)/ALT(SGPT)≤3 × institutional upper limit of normal * creatinine within normal institutional limits OR * creatinine clearance≥60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal * int'l normalized ratio\<1.8 * systolic blood pressure≤160 mmHg * diastolic blood pressure ≥90 mmHg * For women of child-bearing potential, negative serum pregnan…